Chen D, Inzunza Dominguez J, Valle Uzeta J, Pushparaj A, Dickinson J
Front Immunol. 2025; 16:1535782.
PMID: 39981248
PMC: 11839422.
DOI: 10.3389/fimmu.2025.1535782.
Grassi S, Vaiano F, Dimitrova A, Vullo C, Croce E, Rossi R
Int J Legal Med. 2025; .
PMID: 39937272
DOI: 10.1007/s00414-025-03439-9.
Iyer R, Favela D, Domokos A, Zhang G, Avanes A, Carter S
Nat Chem. 2025; 17(3):412-420.
PMID: 39915657
DOI: 10.1038/s41557-024-01714-7.
Nahlawi A, Ptaszek L, Ruskin J
Nat Cardiovasc Res. 2025; 4(2):131-144.
PMID: 39910289
DOI: 10.1038/s44161-025-00608-2.
Knuijver T, Ter Heine R, Schellekens A, Heydari P, Lucas L, Westra S
J Psychopharmacol. 2024; 38(5):481-488.
PMID: 38519421
PMC: 11102648.
DOI: 10.1177/02698811241237873.
Case report: Ibogaine reduced severe neuropathic pain associated with a case of brachial plexus nerve root avulsion.
Dickinson J, Inzunza J, Perez-Villa L, Millar T, Pushparaj A
Front Pain Res (Lausanne). 2023; 4:1256396.
PMID: 37720911
PMC: 10502345.
DOI: 10.3389/fpain.2023.1256396.
Identifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies.
Rocha J, Reis J, Bouso J, Hallak J, Dos Santos R
Eur Arch Psychiatry Clin Neurosci. 2023; 273(7):1527-1542.
PMID: 36947216
DOI: 10.1007/s00406-023-01590-1.
Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature.
Mosca A, Chiappini S, Miuli A, Mancusi G, Santovito M, Di Carlo F
Curr Neuropharmacol. 2022; 21(11):2178-2194.
PMID: 36263479
PMC: 10556383.
DOI: 10.2174/1570159X21666221017085612.
Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders.
Vorobyeva N, Kozlova A
Front Pharmacol. 2022; 13:927984.
PMID: 35837277
PMC: 9274002.
DOI: 10.3389/fphar.2022.927984.
The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020).
Ona G, Rocha J, Bouso J, Hallak J, Borras T, Colomina M
Psychopharmacology (Berl). 2021; 239(6):1977-1987.
PMID: 34406452
DOI: 10.1007/s00213-021-05964-y.
Psychoactive Substances of Natural Origin: Toxicological Aspects, Therapeutic Properties and Analysis in Biological Samples.
Goncalves J, Luis A, Gallardo E, Duarte A
Molecules. 2021; 26(5).
PMID: 33807728
PMC: 7961374.
DOI: 10.3390/molecules26051397.
Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study.
Knuijver T, Schellekens A, Belgers M, Donders R, van Oosteren T, Kramers K
Addiction. 2021; 117(1):118-128.
PMID: 33620733
PMC: 9292417.
DOI: 10.1111/add.15448.
A non-hallucinogenic psychedelic analogue with therapeutic potential.
Cameron L, Tombari R, Lu J, Pell A, Hurley Z, Ehinger Y
Nature. 2020; 589(7842):474-479.
PMID: 33299186
PMC: 7874389.
DOI: 10.1038/s41586-020-3008-z.
The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs.
Iyer R, Favela D, Zhang G, Olson D
Nat Prod Rep. 2020; 38(2):307-329.
PMID: 32794540
PMC: 7882011.
DOI: 10.1039/d0np00033g.
Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.
Dunn K, Huhn A, Bergeria C, Gipson C, Weerts E
J Pharmacol Exp Ther. 2019; 371(2):422-452.
PMID: 31391211
PMC: 6863456.
DOI: 10.1124/jpet.119.258004.
Cardiac arrest after ibogaine intoxication.
Steinberg C, Deyell M
J Arrhythm. 2018; 34(4):455-457.
PMID: 30167018
PMC: 6111465.
DOI: 10.1002/joa3.12061.
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.
Schenberg E
Front Pharmacol. 2018; 9:733.
PMID: 30026698
PMC: 6041963.
DOI: 10.3389/fphar.2018.00733.
Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes.
Mash D, Duque L, Page B, Allen-Ferdinand K
Front Pharmacol. 2018; 9:529.
PMID: 29922156
PMC: 5996271.
DOI: 10.3389/fphar.2018.00529.
Herbal Highs: Review on Psychoactive Effects and Neuropharmacology.
Graziano S, Orsolini L, Rotolo M, Tittarelli R, Schifano F, Pichini S
Curr Neuropharmacol. 2016; 15(5):750-761.
PMID: 27799032
PMC: 5771051.
DOI: 10.2174/1570159X14666161031144427.
Clinical applications of hallucinogens: A review.
Garcia-Romeu A, Kersgaard B, Addy P
Exp Clin Psychopharmacol. 2016; 24(4):229-68.
PMID: 27454674
PMC: 5001686.
DOI: 10.1037/pha0000084.